
#MondayNightIBD 🎥series kicks off w/ @EdLoftus2 & @DCharabaty discussing #IBD RCTs (&🆓 #CME) x.com/i/broadcasts/2JQeRAqpJ…

Created by @DCharabaty •Join us for #IBD #IBDPoll & convo or #Back2Basics MON ~5pmET • #PatientExperience WED • #IBDAlgorithm THUR • Opinions≠med advice 🆓#CME

#MondayNightIBD 🎥series kicks off w/ @EdLoftus2 & @DCharabaty discussing #IBD RCTs (&🆓 #CME) x.com/i/broadcasts/2JQeRAqpJ…

#IBDPoll 2️⃣ Are you someone living with #IBD or a caregiver? What thought/feeling comes first to mind when we talk about clinical trials for new treatment (Rx) for #IBD ? #MondayNightIBD #PatientExperience

#IBDPoll1️⃣ Are you someone living with #IBD or a caregiver ? Were you ever offered to enroll in a clinical trial for a new treatment for IBD? Would you/Have you ever considered it/participated in a trial? #MondayNightIBD #PatientExperience

🎙️We want to hear from patients & caregivers living w #IBD! Let us know your thoughts on IBD ClinicalTrials👇🏽in the #PrePoll👇🏽 🎥Join the #PatientExperience #webinar this afternoon led by @colorofgi ’s own Reynelda Soltaire✨ Supported by edu grant @JNJInnovMed & @TakedaPharma

Short on time ⌛️ ⏩Need to skip ahead ⛔️1:48 ~ Barriers w traditional RCTs 🪜3:30 ~ Impact of market saturation &🌊 of new tx 🎯5:00 ~ Innovations in trial designs 🔮8:30 ~ MOAs of the future 💬12:45 ~ Pt communication & "how-to" 🤝17:10 ~ Establishing trust & inclusion

🎥 #MondayNightIBD webinar series starts NOW @edloftus2 & @DCharabaty talk #IBD RCTs ⛔️Barriers to enrollment 🧩Innovative trial designs 🤝How to talk to pts about RCTs 🔮MOAs on the horizon Check👇🏽 what’s in the future of #IBD 🧰
#MondayNightIBD 🎥series kicks off w/ @EdLoftus2 & @DCharabaty discussing #IBD RCTs (&🆓 #CME) x.com/i/broadcasts/2JQeRAqpJ…

#IBDPoll1️⃣ 🆓CME👉🏼mnibd.short.gy/LoftusPost In your opinion/ experience, Which feature of the traditional RCT induction (drug vs PBO) + Re-randomize responders during maintenance- design mostly contributes to patient reluctance to enroll in RCT ?

#IBDPoll2️⃣ 🆓CME👉🏼mnibd.short.gy/LoftusPost In your opinion which trial design is more appealing to patients and trial centers in terms of recruitment ?

📱Outlook is out, #MondayNightIBD is in ! Kicking off the🍁season 🎥Nov16: #IBD RCT @EdwardLoftus2: barriers to enrollment, new designs, upcominy🔥trials 🎥Nov18: #PatientExperience 🆓CME👉🏼mnibd.short.gy/26-27 🗳️#IBDpolls👇🏽 Supported by edu grants @JNJInnovMed @TakedaPharma”

Don’t miss this 🧵 on anti-TL1A for #IBD #UC #Crohns! We review the available data of the 3️⃣ upcoming agents for this 🆕 exciting MOA ! @DCharabaty @vipuljairath 👇🏽👇🏽👇🏽
1/ #MondayNightIBD #Back2Basics TL1A , a 🆕🎯for inflammation & ?fibrosis 3️⃣anti-TL1A mAbs w/ Ph 2 trials data +active Ph 3 for #UC & #Crohns ⚙️MOA, efficacy, safety 🆓CME 👉🏼mnibd.short.gy/TL1AsTW Support by an educational grant @Sanofi 📍Where are you in your career?

1/ #MondayNightIBD #Back2Basics TL1A , a 🆕🎯for inflammation & ?fibrosis 3️⃣anti-TL1A mAbs w/ Ph 2 trials data +active Ph 3 for #UC & #Crohns ⚙️MOA, efficacy, safety 🆓CME 👉🏼mnibd.short.gy/TL1AsTW Support by an educational grant @Sanofi 📍Where are you in your career?

2/ #MondayNightIBD 🚧~40% mod-sev #IBD have no or LoR to current Rx 🎯TL1A: TNF superfamily member, binds DR3 on T cells, NK cells & ILCs 🥊Drives inflammation (Th1/Th17/Th2) AND fibrosis (fibroblast activation) 🥊anti-TL1A block TL1A–DR3 →⬇️innate + adaptive immunity

3/#MondayNightIBD 🎬Starting w #Duvakitug 🔥Hot off the press 🩺RELIEVE UCCD: Ph2b basket trial: Parallel UC+CD cohorts (~120 pts each) 💉1 Loading dose DUVA SC→DUVA SC 450mg Q2W vs 900mg Q2W vs PBO 🎯Primary end points @ Wk14 UC: Clin remission CD: Endo response

4/#MondayNightIBD RELIEVE-UCCD📊Wk14 outcomes in UC Bayesian trial→posterior probability(PP) ✅Clin remission(mMS) 48%(900mg)/ 36%(450mg) DUVA vs 20% PBO Δ26% PP >0.99 | Δ15% PP 0.95 ✅Endo Improvemt(MES 0/1) 50%(900mg)/ 45%(450mg) DUVA vs 23% PBO Δ26% PP >0.99 | Δ21% PP 0.99

5/#MondayNightIBD RELIEVE UCCD 📊Wk 14 outcomes in #Crohns 🔦Endo Response (≥50% ↓ SES-CD) 48% (900mg)/ 26% (450mg) DUVA vs 13% PBO Δ33% PP >0.99 | Δ13% PP 0.94 🩺Clinical Remission (PRO2) 37%/37% DUVA vs 26% PBO Δ10% PP 0.87 (both doses)

6/#MondayNightIBD RELIEVE-UCCD LTE 🗞️ release (to be presented at upcoming meeting) 🔀Wk14 responders re-randomized to DUVA 900mg or 450mg SC Q4W to wk44 🎯Wk 44- UC clin remission (mMS) 900 mg: 58% 450 mg: 47% 🎯Wk 44- CD endo response (SES-CD) 900 mg: 55% 450 mg: 41%